Which has stronger valuation & earnings, EHC or MEDP?

Encompass Health has higher revenue and earnings than Medpace. Encompass Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Encompass Health $5.94B 1.83 $566.20M $5.99 18.31 Medpace $2.53B 6.08 $451.12M $15.91 33.83

Does the media refer more to EHC or MEDP?

In the previous week, Encompass Health had 1 more articles in the media than Medpace. MarketBeat recorded 7 mentions for Encompass Health and 6 mentions for Medpace. Encompass Health's average media sentiment score of 0.83 beat Medpace's score of 0.00 indicating that Encompass Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Encompass Health 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, MEDP or ELV?

Elevance Health has higher revenue and earnings than Medpace. Elevance Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 6.08 $451.12M $15.91 33.83 Elevance Health $199.13B 0.45 $5.66B $23.51 17.72

Is MEDP or ELV more profitable?

Medpace has a net margin of 17.19% compared to Elevance Health's net margin of 2.62%. Medpace's return on equity of 120.89% beat Elevance Health's return on equity. Company Net Margins Return on Equity Return on Assets Medpace 17.19% 120.89% 24.79% Elevance Health 2.62% 15.58% 5.57%

Does the media favor MEDP or ELV?

In the previous week, Elevance Health had 13 more articles in the media than Medpace. MarketBeat recorded 19 mentions for Elevance Health and 6 mentions for Medpace. Elevance Health's average media sentiment score of 1.11 beat Medpace's score of 0.00 indicating that Elevance Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Elevance Health 13 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, MEDP or HIMS?

Medpace has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 6.08 $451.12M $15.91 33.83 Hims & Hers Health $2.35B 3.40 $128.37M -$0.09 N/A

Does the media favor MEDP or HIMS?

In the previous week, Hims & Hers Health had 4 more articles in the media than Medpace. MarketBeat recorded 10 mentions for Hims & Hers Health and 6 mentions for Medpace. Hims & Hers Health's average media sentiment score of 0.80 beat Medpace's score of 0.00 indicating that Hims & Hers Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hims & Hers Health 6 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, IQV or MEDP?

IQVIA has higher revenue and earnings than Medpace. IQVIA is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IQVIA $16.31B 2.13 $1.36B $8.07 25.79 Medpace $2.53B 6.08 $451.12M $15.91 33.83

Is IQV or MEDP more profitable?

Medpace has a net margin of 17.19% compared to IQVIA's net margin of 8.33%. Medpace's return on equity of 120.89% beat IQVIA's return on equity. Company Net Margins Return on Equity Return on Assets IQVIA 8.33% 30.50% 6.53% Medpace 17.19% 120.89% 24.79%

Does the media refer more to IQV or MEDP?

In the previous week, IQVIA had 8 more articles in the media than Medpace. MarketBeat recorded 14 mentions for IQVIA and 6 mentions for Medpace. IQVIA's average media sentiment score of 1.03 beat Medpace's score of 0.00 indicating that IQVIA is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IQVIA 10 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer MEDP or RELX?

Medpace currently has a consensus price target of $469.17, suggesting a potential downside of 12.83%. Given Medpace's higher possible upside, analysts plainly believe Medpace is more favorable than Relx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medpace 1 Sell rating(s) 12 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.07 Relx 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has higher valuation & earnings, MEDP or RELX?

Relx has higher revenue and earnings than Medpace. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 6.08 $451.12M $15.91 33.83 Relx $12.64B 4.54 $2.72B N/A N/A

Is MEDP or RELX more profitable?

Medpace has a net margin of 17.19% compared to Relx's net margin of 0.00%. Medpace's return on equity of 120.89% beat Relx's return on equity. Company Net Margins Return on Equity Return on Assets Medpace 17.19% 120.89% 24.79% Relx N/A N/A N/A

Does the media refer more to MEDP or RELX?

In the previous week, Medpace had 4 more articles in the media than Relx. MarketBeat recorded 6 mentions for Medpace and 2 mentions for Relx. Medpace's average media sentiment score of 0.00 equaled Relx'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Relx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Medpace (MEDP) Competitors

$538.23 +2.73 (+0.51%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$538.09 -0.14 (-0.03%)

As of 07/10/2026 04:10 PM Eastern

Compare

MEDP vs. EHC, ELV, HIMS, IQV, and RELX

Should you buy Medpace stock or one of its competitors? MarketBeat compares Medpace with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Medpace include Encompass Health (EHC), Elevance Health (ELV), Hims & Hers Health (HIMS), IQVIA (IQV), and Relx (RELX).

How does Medpace compare to Encompass Health?

Encompass Health (NYSE:EHC) and Medpace (NASDAQ:MEDP) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

97.3% of Encompass Health shares are held by institutional investors. Comparatively, 78.0% of Medpace shares are held by institutional investors. 1.8% of Encompass Health shares are held by insiders. Comparatively, 20.5% of Medpace shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Encompass Health presently has a consensus target price of $143.86, indicating a potential upside of 31.14%. Medpace has a consensus target price of $469.17, indicating a potential downside of 12.83%. Given Encompass Health's stronger consensus rating and higher possible upside, research analysts plainly believe Encompass Health is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Encompass Health	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.89
Medpace	1 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.07

Medpace has a net margin of 17.19% compared to Encompass Health's net margin of 10.04%. Medpace's return on equity of 120.89% beat Encompass Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Encompass Health	10.04%	18.28%	8.27%
Medpace	17.19%	120.89%	24.79%

Encompass Health has higher revenue and earnings than Medpace. Encompass Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Encompass Health	$5.94B	1.83	$566.20M	$5.99	18.31
Medpace	$2.53B	6.08	$451.12M	$15.91	33.83

In the previous week, Encompass Health had 1 more articles in the media than Medpace. MarketBeat recorded 7 mentions for Encompass Health and 6 mentions for Medpace. Encompass Health's average media sentiment score of 0.83 beat Medpace's score of 0.00 indicating that Encompass Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Encompass Health	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Encompass Health has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Medpace has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

Summary

Encompass Health beats Medpace on 9 of the 17 factors compared between the two stocks.

How does Medpace compare to Elevance Health?

Medpace (NASDAQ:MEDP) and Elevance Health (NYSE:ELV) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

In the previous week, Elevance Health had 13 more articles in the media than Medpace. MarketBeat recorded 19 mentions for Elevance Health and 6 mentions for Medpace. Elevance Health's average media sentiment score of 1.11 beat Medpace's score of 0.00 indicating that Elevance Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elevance Health	13 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Medpace has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Elevance Health has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

78.0% of Medpace shares are held by institutional investors. Comparatively, 89.2% of Elevance Health shares are held by institutional investors. 20.5% of Medpace shares are held by company insiders. Comparatively, 0.3% of Elevance Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Elevance Health has higher revenue and earnings than Medpace. Elevance Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	6.08	$451.12M	$15.91	33.83
Elevance Health	$199.13B	0.45	$5.66B	$23.51	17.72

Medpace currently has a consensus target price of $469.17, suggesting a potential downside of 12.83%. Elevance Health has a consensus target price of $425.95, suggesting a potential upside of 2.26%. Given Elevance Health's stronger consensus rating and higher possible upside, analysts clearly believe Elevance Health is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	1 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.07
Elevance Health	0 Sell rating(s)	9 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.63

Medpace has a net margin of 17.19% compared to Elevance Health's net margin of 2.62%. Medpace's return on equity of 120.89% beat Elevance Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.19%	120.89%	24.79%
Elevance Health	2.62%	15.58%	5.57%

Summary

Elevance Health beats Medpace on 9 of the 16 factors compared between the two stocks.

How does Medpace compare to Hims & Hers Health?

Medpace (NASDAQ:MEDP) and Hims & Hers Health (NYSE:HIMS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

In the previous week, Hims & Hers Health had 4 more articles in the media than Medpace. MarketBeat recorded 10 mentions for Hims & Hers Health and 6 mentions for Medpace. Hims & Hers Health's average media sentiment score of 0.80 beat Medpace's score of 0.00 indicating that Hims & Hers Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hims & Hers Health	6 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Medpace presently has a consensus price target of $469.17, indicating a potential downside of 12.83%. Hims & Hers Health has a consensus price target of $30.70, indicating a potential downside of 10.88%. Given Hims & Hers Health's stronger consensus rating and higher possible upside, analysts clearly believe Hims & Hers Health is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	1 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.07
Hims & Hers Health	2 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13

Medpace has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	6.08	$451.12M	$15.91	33.83
Hims & Hers Health	$2.35B	3.40	$128.37M	-$0.09	N/A

78.0% of Medpace shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 20.5% of Medpace shares are held by company insiders. Comparatively, 11.8% of Hims & Hers Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Medpace has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.35, indicating that its stock price is 135% more volatile than the broader market.

Medpace has a net margin of 17.19% compared to Hims & Hers Health's net margin of -0.56%. Medpace's return on equity of 120.89% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.19%	120.89%	24.79%
Hims & Hers Health	-0.56%	6.10%	1.52%

Summary

Medpace beats Hims & Hers Health on 10 of the 16 factors compared between the two stocks.

How does Medpace compare to IQVIA?

IQVIA (NYSE:IQV) and Medpace (NASDAQ:MEDP) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

In the previous week, IQVIA had 8 more articles in the media than Medpace. MarketBeat recorded 14 mentions for IQVIA and 6 mentions for Medpace. IQVIA's average media sentiment score of 1.03 beat Medpace's score of 0.00 indicating that IQVIA is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IQVIA	10 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

89.6% of IQVIA shares are held by institutional investors. Comparatively, 78.0% of Medpace shares are held by institutional investors. 1.7% of IQVIA shares are held by company insiders. Comparatively, 20.5% of Medpace shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Medpace has a net margin of 17.19% compared to IQVIA's net margin of 8.33%. Medpace's return on equity of 120.89% beat IQVIA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.33%	30.50%	6.53%
Medpace	17.19%	120.89%	24.79%

IQVIA has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market. Comparatively, Medpace has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

IQVIA currently has a consensus price target of $224.82, suggesting a potential upside of 8.02%. Medpace has a consensus price target of $469.17, suggesting a potential downside of 12.83%. Given IQVIA's stronger consensus rating and higher possible upside, equities research analysts clearly believe IQVIA is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.82
Medpace	1 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.07

IQVIA has higher revenue and earnings than Medpace. IQVIA is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.31B	2.13	$1.36B	$8.07	25.79
Medpace	$2.53B	6.08	$451.12M	$15.91	33.83

Summary

IQVIA beats Medpace on 9 of the 16 factors compared between the two stocks.

How does Medpace compare to Relx?

Medpace (NASDAQ:MEDP) and Relx (NYSE:RELX) are both large-cap business services companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Medpace currently has a consensus price target of $469.17, suggesting a potential downside of 12.83%. Given Medpace's higher possible upside, analysts plainly believe Medpace is more favorable than Relx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	1 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.07
Relx	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Medpace had 4 more articles in the media than Relx. MarketBeat recorded 6 mentions for Medpace and 2 mentions for Relx. Medpace's average media sentiment score of 0.00 equaled Relx'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Relx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

78.0% of Medpace shares are held by institutional investors. Comparatively, 15.0% of Relx shares are held by institutional investors. 20.5% of Medpace shares are held by insiders. Comparatively, 0.0% of Relx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Medpace has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Relx has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

Relx has higher revenue and earnings than Medpace.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	6.08	$451.12M	$15.91	33.83
Relx	$12.64B	4.54	$2.72B	N/A	N/A

Medpace has a net margin of 17.19% compared to Relx's net margin of 0.00%. Medpace's return on equity of 120.89% beat Relx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.19%	120.89%	24.79%
Relx	N/A	N/A	N/A

Summary

Medpace beats Relx on 9 of the 14 factors compared between the two stocks.

Get Medpace News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MEDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MEDP vs. The Competition

Export

Metric	Medpace	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$15.29B	$9.46B	$7.12B	$12.61B
Dividend Yield	N/A	1.63%	2.68%	7.83%
P/E Ratio	33.83	25.73	27.22	24.56
Price / Sales	6.08	17.88	590.16	121.71
Price / Cash	31.48	114.05	49.34	60.04
Price / Book	33.02	6.05	10.90	6.39
Net Income	$451.12M	$177.20M	$3.57B	$331.44M
7 Day Performance	-3.47%	-1.71%	-0.25%	0.37%
1 Month Performance	13.29%	9.00%	5.77%	2.17%
1 Year Performance	66.38%	10.51%	28.14%	20.90%

Medpace Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MEDP Medpace	1.6387 of 5 stars	$538.23 +0.5%	$469.17 -12.8%	+64.0%	$15.29B	$2.53B	33.83	6,200	Analyst Downgrade
EHC Encompass Health	4.8666 of 5 stars	$106.98 +0.5%	$143.86 +34.5%	-6.7%	$10.56B	$5.94B	17.86	42,000	Positive News
ELV Elevance Health	4.6377 of 5 stars	$408.35 -2.3%	$419.16 +2.6%	+20.6%	$90.75B	$199.13B	17.37	97,100	Positive News Upcoming Earnings Analyst Forecast
HIMS Hims & Hers Health	3.0306 of 5 stars	$38.34 +4.2%	$30.63 -20.1%	-31.4%	$8.52B	$2.35B	N/A	2,442	Analyst Forecast Insider Trade
IQV IQVIA	4.0758 of 5 stars	$206.07 -0.5%	$223.88 +8.6%	+25.7%	$34.55B	$16.31B	25.54	93,000	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MEDP) was last updated on 7/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medpace (MEDP) Competitors

MEDP vs. EHC, ELV, HIMS, IQV, and RELX

How does Medpace compare to Encompass Health?

Summary

How does Medpace compare to Elevance Health?

Summary

How does Medpace compare to Hims & Hers Health?

Summary

How does Medpace compare to IQVIA?

Summary

How does Medpace compare to Relx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MEDP vs. The Competition

Medpace Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medpace (MEDP) Competitors

MEDP vs. EHC, ELV, HIMS, IQV, and RELX

How does Medpace compare to Encompass Health?

Do insiders and institutionals believe in EHC or MEDP?

Do analysts recommend EHC or MEDP?

Is EHC or MEDP more profitable?

Which has stronger valuation & earnings, EHC or MEDP?

Does the media refer more to EHC or MEDP?

Which has more risk and volatility, EHC or MEDP?

Summary

How does Medpace compare to Elevance Health?

Does the media favor MEDP or ELV?

Which has more volatility & risk, MEDP or ELV?

Do institutionals and insiders have more ownership in MEDP or ELV?

Which has stronger earnings & valuation, MEDP or ELV?

Do analysts prefer MEDP or ELV?

Is MEDP or ELV more profitable?

Summary

How does Medpace compare to Hims & Hers Health?

Does the media favor MEDP or HIMS?

Do analysts recommend MEDP or HIMS?

Which has higher valuation and earnings, MEDP or HIMS?

Do institutionals and insiders hold more shares of MEDP or HIMS?

Which has more risk and volatility, MEDP or HIMS?

Is MEDP or HIMS more profitable?

Summary

How does Medpace compare to IQVIA?

Does the media refer more to IQV or MEDP?

Do institutionals & insiders believe in IQV or MEDP?

Is IQV or MEDP more profitable?

Which has more volatility and risk, IQV or MEDP?

Do analysts prefer IQV or MEDP?

Which has preferable earnings & valuation, IQV or MEDP?

Summary

How does Medpace compare to Relx?

Do analysts prefer MEDP or RELX?

Does the media refer more to MEDP or RELX?

Do institutionals & insiders hold more shares of MEDP or RELX?

Which has more risk and volatility, MEDP or RELX?

Which has higher valuation & earnings, MEDP or RELX?

Is MEDP or RELX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MEDP vs. The Competition

Medpace Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools